Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Pilar Mendoza, Henning Gruell, Lilian Nogueira...
https://pubmed.ncbi.nlm.nih.gov/30258136/Actively Recruiting
Led by Imperial College London · Updated on 2024-04-17
72
Participants Needed
12
Research Sites
N/A
Total Duration
Researchers are evaluating the use of dual long-acting broadly neutralising antibodies bNAbs, 3BNC117-LS and 10-1074-LS, in adults living with HIV who started antiretroviral therapy ART early during primary HIV infection. This phase II randomized, placebo-controlled, double-blinded trial aims to determine whether these antibodies can control HIV replication when ART is paused. The study includes adults aged 18 to 60 years who have been on suppressive ART for at least 12 months. Participants will be randomly assigned to one of two groups one receiving ART plus infusions of the dual long-acting bNAbs followed by a monitored interruption of ART, and the other receiving ART plus placebo infusions followed by ART interruption. Those in the placebo group will later receive the bNAbs and undergo a second interruption of ART. The study will monitor the time to viral rebound after stopping ART, with treatment resumption and further monitoring as needed. During the study, participants will attend regular visits for blood sampling, assessments, and close monitoring of viral load to detect HIV rebound. Researchers will evaluate how long it takes for the virus to return after stopping ART, up to 20 weeks. Participants must comply with study procedures, including follow-up visits and blood tests, and will be monitored for safety throughout the study, which continues until viral rebound or study completion.
CONDITIONS
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
S
Stephen Fletcher
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Imperial College London
Lead Sponsor
Bill and Melinda Gates Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 20 weeks or until viral rebound occurs
Participants receive infusions of either dual long-acting broadly neutralising antibodies or placebo alongside antiretroviral therapy, followed by a monitored interruption of antiretroviral treatment to assess viral control.
Weekly visits for up to 20 weeks during treatment interruption
Duration - Up to 24 weeks after antibody infusion
Participants who restart antiretroviral therapy after viral rebound receive additional antibody infusions and may undergo a second treatment interruption, with continued monitoring.
Approximately 6 to 8 follow-up visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Pilar Mendoza, Henning Gruell, Lilian Nogueira...
https://pubmed.ncbi.nlm.nih.gov/30258136/SPARTAC Trial Investigators, Sarah Fidler, Kholoud Porter...
https://pubmed.ncbi.nlm.nih.gov/23323897/Yoshiaki Nishimura, Rajeev Gautam, Tae-Wook Chun...
https://pubmed.ncbi.nlm.nih.gov/28289286/Johannes F Scheid, Joshua A Horwitz, Yotam Bar-On...
https://pubmed.ncbi.nlm.nih.gov/27338952/Golnaz Namazi, Jesse M Fajnzylber, Evgenia Aga...
https://pubmed.ncbi.nlm.nih.gov/30085241/Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou...
https://pubmed.ncbi.nlm.nih.gov/42202839/Imperial College London
Lead Sponsor
Bill and Melinda Gates Foundation
Collaborating Sponsor